At PCI, ensuring life-changing medicines reach those who need it most is our highest priority. As a truly integrated global CDMO, we are manufacturing, packaging and supply chain experts, harnessing our experience and expertise to deliver you a seamless solution with the ultimate aim of improving the lives of patients.
Traditional product development of a formulated solid oral drug for Phase I clinical trials typically involves a range of activities including initial compatibility studies, analytical method development, prototype development, short term stability, process/formulation refinement, Phase I method validation, and finally, clinical manufacture.
Xcelodose® micro-dosing technology removes the need for initial formulation development and the associated stability testing, enabling PCI to achieve fast times to first-in-human (FIH) studies on behalf of its clients.
The fully programmable system ensures exceptional levels of accuracy and precision whilst minimizing wastage of drug substance. We are proud to offer multiple options of micro-dosing technology, delivering individual
client volume requirements.
PCI has further invested in Xcelohood™ and Xceloprotect™ containment technology, further enhancing our contained solutions for the development and manufacturing of highly potent drug products.
Features of Xcelodose® Technology
Our dedicated team of specialists will be happy to discuss any of your Xcelodose Micro-dosing Technology questions. Contact us on +1 779-208-1819 (US) or +44 1495 711 222 (UK/EU) or email email@example.com
Contact us. Get ready to experience true speed.
Rely on our Xcelodose® micro-dosing technology to expedite your drug product journey.